Role of TGF-Beta in the Recruitment of Bone Marrow Progenitors in Vascular Injury
TGF-β 在血管损伤中骨髓祖细胞募集中的作用
基本信息
- 批准号:8002708
- 负责人:
- 金额:$ 4.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2011-06-23
- 项目状态:已结题
- 来源:
- 关键词:AngioplastyArterial InjuryArteriesAtherosclerosisBlood VesselsBone MarrowBone Marrow CellsBypassCell ProliferationComplexDevelopmentEndarterectomyExtracellular MatrixFibroblastsGenesHyperplasiaInjuryInterventionLeadLesionMediatingMolecularMonocyte Chemoattractant Protein-1Operative Surgical ProceduresPatientsPlayProcessProductionProliferatingRecruitment ActivityRoleSignal TransductionSignaling ProteinSiteSmooth Muscle MyocytesStem cellsTransforming Growth Factor betaarterial remodelingcell typechemokineinjuredpreventprogenitorpublic health relevancerestenosistherapy development
项目摘要
DESCRIPTION (provided by applicant): Restenosis is a significant impediment to treatments for atherosclerosis including bypass surgery, endarterectomy, and angioplasty and stenting, and occurs in up to 30- 50% of patients following angioplasty and stenting. Understanding the molecular mechanisms that drive neointimal hyperplasia and arterial remodeling, two main contributors to restenosis, will ultimately allow for the development of therapies that prevent or halt the progression of this serious process. Restenosis is in part caused by a complex process called intimal hyperplasia. The neointimal lesion is comprised of proliferating smooth muscle cells (SMCs) and extracellular matrix. New evidence suggests that bone marrow-derived progenitor cells (BMPCs) recruited to sites of vascular injury also contribute to the neointima. BMPCs are considered multipotent in that they are capable of differentiating into numerous cell types including fibroblasts and SMCs. However, the mechanisms through which progenitor cells are recruited into the injured artery have not been described. Transforming Growth Factor-Beta (TGF-Beta), upregulated at the site of vascular injury, plays a critical role in the genesis of restenosis following vascular intervention. Our previous studies revealed that TGF-Beta's contribution to intimal hyperplasia is primarily related to cell proliferation and matrix remodeling. Moreover, TGF-Beta through its actions on SMCs may also significantly enhance progenitor cell recruitment. TGF-Beta's effect may be mediated by its signaling protein, Smad3, and lead to the production of chemokines by SMCs. Our gene array studies have demonstrated that in TGF-Beta-stimulated Smad3-expressing SMCs, Monocyte Chemotactic Protein-1 (MCP-1) is expressed over 80-fold. Our hypothesis is that TGF-Beta, through Smad3 signaling, stimulates SMCs to produce chemokines such as MCP-1, which attract bone marrow cells to the site of arterial injury thereby enhancing the development of intimal hyperplasia.
PUBLIC HEALTH RELEVANCE: Restenosis is a significant impediment to treatments for atherosclerosis and occurs in up to 30-50% of patients following vascular interventions. Bone marrow-derived progenitor cells have been found to contribute to neointimal hyperplasia, one of the two main contributors to restenosis. However, the mechanisms through which progenitor cells are recruited have not been described. Our hypothesis is that TGF-Beta, through Smad3 signaling, stimulates smooth muscle cells in the vascular wall to produce factors such as monocyte chemoattractant protein-1 to attract bone marrow cells to sites of arterial injury.
描述(由申请人提供):再狭窄是动脉粥样硬化治疗的重大障碍,包括搭桥手术,内部切除术以及血管成形术和支架,并发生在血管成形术和支架后多达30%至50%的患者中。了解驱动新内膜增生和动脉重塑的分子机制,这是再狭窄的两个主要因素,最终将允许开发预防或阻止这种严重过程发展的疗法。再狭窄部分是由称为内膜增生的复杂过程引起的。新内膜病变由增殖的平滑肌细胞(SMC)和细胞外基质组成。新的证据表明,招募到血管损伤部位的骨髓衍生的祖细胞(BMPC)也有助于新神经。 BMPC被认为是多能,因为它们能够区分多种细胞类型,包括成纤维细胞和SMC。然而,尚未描述将祖细胞募集到受伤的动脉中的机制。在血管损伤部位上调的转化生长因子β(TGF-β)在血管干预后的再狭窄起源中起着至关重要的作用。我们先前的研究表明,TGF-β对内膜增生的贡献主要与细胞增殖和基质重塑有关。此外,TGF-beta通过其对SMC的作用也可能显着增强祖细胞募集。 TGF-β的作用可能是由其信号蛋白SMAD3介导的,并导致SMC的趋化因子产生。我们的基因阵列研究表明,在TGF-beta刺激的表达SMC中,单核细胞趋化蛋白-1(MCP-1)的表达超过80倍。我们的假设是,通过SMAD3信号传导,TGF-beta刺激了SMC以产生趋化因子,例如MCP-1,这些趋化因子吸引了骨髓细胞到动脉损伤部位,从而增强了内膜增生的发展。
公共卫生相关性:再狭窄是动脉粥样硬化治疗的重大障碍,在血管干预后,多达30-50%的患者发生。已经发现骨髓来源的祖细胞有助于新内膜增生,这是再狭窄的两个主要因素之一。但是,尚未描述募集祖细胞的机制。我们的假设是,通过SMAD3信号传导TGF-beta刺激血管壁中的平滑肌细胞产生诸如单核细胞化学吸引蛋白-1的因素,以吸引骨髓细胞到动脉损伤部位。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pasithorn Suwanabol其他文献
Pasithorn Suwanabol的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pasithorn Suwanabol', 18)}}的其他基金
Risk stratified survivorship care pathways for early-onset colorectal cancer
早发性结直肠癌的风险分层生存护理途径
- 批准号:
10560031 - 财政年份:2023
- 资助金额:
$ 4.39万 - 项目类别:
Earlier Introductions to Palliative Care in Older Adults Undergoing High-Risk Surgery
早期介绍接受高风险手术的老年人的姑息治疗
- 批准号:
10000817 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Optimizing the End-of-Life Care Needs of Older Adults Undergoing Surgery
优化接受手术的老年人的临终护理需求
- 批准号:
9891641 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Optimizing the End-of-Life Care Needs of Older Adults Undergoing Surgery
优化接受手术的老年人的临终护理需求
- 批准号:
10020959 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Optimizing the End-of-Life Care Needs of Older Adults Undergoing Surgery
优化接受手术的老年人的临终护理需求
- 批准号:
10490269 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Optimizing the End-of-Life Care Needs of Older Adults Undergoing Surgery
优化接受手术的老年人的临终护理需求
- 批准号:
10707145 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Earlier Introductions to Palliative Care in Older Adults Undergoing High-Risk Surgery
早期介绍接受高风险手术的老年人的姑息治疗
- 批准号:
9812080 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
Optimizing the End-of-Life Care Needs of Older Adults Undergoing Surgery
优化接受手术的老年人的临终护理需求
- 批准号:
10265468 - 财政年份:2019
- 资助金额:
$ 4.39万 - 项目类别:
相似国自然基金
GSDME介导的内皮细胞损伤在阿霉素促进动脉粥样硬化中的机制研究
- 批准号:82370452
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于RNA m6A甲基化调控细胞程序性坏死探讨缺硒鸡动脉损伤机制的研究
- 批准号:32372967
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
股腘动脉的本构模型构建及其基于有限元的支架介入动脉损伤机理研究
- 批准号:12302081
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
EZH2调控BK通道在血糖波动加剧冠状动脉功能损伤中的作用及机制研究
- 批准号:82370342
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
Occludin调控内皮细胞紧密连接损伤在动脉粥样硬化中的作用及机制研究
- 批准号:82370447
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Biocarpet: The Next Generation Endovascular Device for Peripheral Arterial Disease
Biocarpet:治疗外周动脉疾病的下一代血管内装置
- 批准号:
10744597 - 财政年份:2023
- 资助金额:
$ 4.39万 - 项目类别:
Development of a multi-modal targeted nanotherapeutic to prevent restenosis in an atherosclerotic environment
开发多模式靶向纳米治疗药物以预防动脉粥样硬化环境中的再狭窄
- 批准号:
10667411 - 财政年份:2022
- 资助金额:
$ 4.39万 - 项目类别:
In vivo vascular delivery of an MK2 inhibitory peptide for the prevention of smooth muscle cell phenotype switch and intimal hyperplasia.
MK2 抑制肽的体内血管递送可预防平滑肌细胞表型转换和内膜增生。
- 批准号:
10729846 - 财政年份:2022
- 资助金额:
$ 4.39万 - 项目类别:
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease
刺激外周动脉疾病治疗性血管生成的新型纳米颗粒
- 批准号:
10756875 - 财政年份:2022
- 资助金额:
$ 4.39万 - 项目类别:
Endothelial Healing is Inhibited by Activation of TRPC6 Channels
TRPC6 通道的激活会抑制内皮愈合
- 批准号:
10369226 - 财政年份:2022
- 资助金额:
$ 4.39万 - 项目类别: